Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Application of next generation sequencing

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.12
Views: 7634
Rating:

Dr Gary Palmer – Foundation Medicine, Cambridge, USA

Dr Gary Palmer talks to ecancer at the 2012 WIN Symposium, Paris, about the FP7 project, WINTHER, which investigates next generation sequencing.

 

The WINTer project uses next generation sequencing by using paraffin tissue; however, the information created must be able to translate for use by a clinical oncologist in a practical setting.

 

Foundation Medicine’s involvement in the WINTHER trial is in the technology arm of the study, Arm A specifically. This involves identifying abnormalities in a patient’s tumour to better identify the best course of treatment. This can be used with either currently available drugs or drugs in clinical trials. 

 

Filming Supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation